What types of innovations are eligible for support?
NICE Guidance
for High Performing MedTech Products
an Accelerated Access Scheme
![['NICE Guidance\r', 'for High Performing MedTech Products\r', 'an Accelerated Access Scheme']](/sites/igesgroup/deviceaccess.eu/myzms/content/e45/e208/nice_guidance.jpg)
NICE has today published further guidance on how high-performing products will be identified and selected by the Accelerated Access Collaborative (AAC) and how support will be offered to them;
Each year, the Accelerated Access Collaborative (AAC) will identify and support innovations that will have the biggest impact on patient outcomes and NHS services. The AAC will consider a full range of innovations across the development pipeline, including – medicines, therapeutic products, medical technologies, digital products and diagnostic products.
The AAC will take a “flexible and pragmatic approach” to identify game-changing innovations which may not be cost-neutral in year but are assessed by NICE to be both clinically and cost-effective.
Areas of interest for the AAC include:
- evidence of clinical and cost effectiveness
- addressing significant unmet need
- application to large populations or high budget impact
- enabling a novel mode of action or enabling significant changes to the care pathway.
What type of support can a product expect to receive?
Products designated as high potential will receive a tailored package of support, with dedicated case management. The AAC partners and the company will agree this based on their development or accelerated needs.
Want to find out more?
To find out more please contact Device Access here
Since 2010 Device Access UK have supported over 30 MedTech Companies through various NICE Programmes including Interventional Procedures (IPG), MedTech Guidance (MTG) and Diagnostic Assessments (DAP), as well as NICE MedTech Innovation Briefings (MIB)
Most recent
Accelerating MedTech Evidence Generation with the NIHR
February 11 2021
NHS England Announce New Funding Mechanism for Innovative MedTech
January 27 2021
How Changes in NHS Funding May Affect Your MedTech Adoption Journey
November 25 2020
The Power of the Patient's Voice in NHS MedTech Adoption
July 16 2020
What is NICE Recommendation and Why is it Useful?
July 10 2020
What is MedTech Market Access?
June 04 2020
Planning Your Engagement Strategy
with the NHS Post-Covid-19
June 04 2020
“Battle Stations”: MedTech Can Fight Against Unseen Enemies Like Covid-19
April 02 2020
MedTech Industry
Engagement with NHS
England after Covid-19
March 20 2020
New NHS England MedTech
Funding Mandate Proposal
– to get innovative
medical devices, diagnostics and
digital products to patients faster
November 16 2019
Innovative Approach That Gets
Patients Back Into
Their Own Homes After Hospital
Stay Honoured - NHS England
July 25 2019
Health Technology
Evaluation Methods
July 23 2019
NHS England Medical Device
Reimbursement Opportunities
July 01 2019
NICE Guidance
for High Performing MedTech Products
an Accelerated Access Scheme
May 02 2019
IGES Institut GmbH
Acquires Majority Shareholding in
Device Access UK
March 04 2019
NICE Approves New Minimally Invasive Steam
Ablation Treatment for Benign Prostatic
Hyperplasia
August 21 2018
Device Access CEO Presenting
at NIHR Surgical MedTech Cooperative
National Meeting 2018 –
Leeds Wednesday 7th November 2018
October 02 2018
Device Access CEO Presenting at 2018
MedTech Reimbursement Roundtable
Zurich Tuesday October 30th
October 02 2018
NICE Today recommend
iFuse for treating chronic
sacroiliac joint pain
October 02 2018
NHS England is Calling on the Best
Innovators from Across the World to
Apply to Join New NHS Adoption Scheme
to Ensure Patients Benefit from New
Technology Faster.
September 14 2018
Device Acccess is Attending Medical Alley Innovation Summit
October 2nd 2018
September 06 2018
Device Access Attending Advamed
Philadelphia
24th-27th September 2018
August 22 2018